BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 7805048)

  • 21. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
    J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration.
    Teitz-Tennenbaum S; Li Q; Rynkiewicz S; Ito F; Davis MA; McGinn CJ; Chang AE
    Cancer Res; 2003 Dec; 63(23):8466-75. PubMed ID: 14679011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector.
    Tanaka F; Abe M; Akiyoshi T; Nomura T; Sugimachi K; Kishimoto T; Suzuki T; Okada M
    Cancer Res; 1997 Apr; 57(7):1335-43. PubMed ID: 9102222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor activity of a human cytotoxic T-cell line (TALL-104) in brain tumor xenografts.
    Geoerger B; Tang CB; Cesano A; Visonneau S; Marwaha S; Judy KD; Sutton LN; Santoli D; Phillips PC
    Neuro Oncol; 2000 Apr; 2(2):103-13. PubMed ID: 11303619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
    Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.
    Tatsumi T; Takehara T; Kanto T; Miyagi T; Kuzushita N; Sugimoto Y; Jinushi M; Kasahara A; Sasaki Y; Hori M; Hayashi N
    Cancer Res; 2001 Oct; 61(20):7563-7. PubMed ID: 11606395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dendritic cells pulsed with apoptotic squamous cell carcinoma have anti-tumor effects when combined with interleukin-2.
    Son YI; Mailliard RB; Watkins SC; Lotze MT
    Laryngoscope; 2001 Aug; 111(8):1472-8. PubMed ID: 11568586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regional treatment of hepatic micrometastasis by adenovirus vector-mediated delivery of interleukin-2 and interleukin-12 cDNAs to the hepatic parenchyma.
    Hirschowitz EA; Naama HA; Evoy D; Lieberman MD; Daly J; Crystal RG
    Cancer Gene Ther; 1999; 6(6):491-8. PubMed ID: 10608345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy of intracranial G422 glioblastoma with dendritic cells pulsed with tumor extract or RNA.
    Zhang Z; Tang LL; Zhan RY; Tong Y; Yao HP; Du LA
    J Zhejiang Univ Sci; 2004 Oct; 5(10):1298-303. PubMed ID: 15362204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
    Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
    J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells.
    Andrews KJ; Ribas A; Butterfield LH; Vollmer CM; Eilber FC; Dissette VB; Nelson SD; Shintaku P; Mekhoubad S; Nakayama T; Taniguchi M; Glaspy JA; McBride WH; Economou JS
    Cancer Res; 2000 Nov; 60(22):6457-64. PubMed ID: 11103813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
    Guinn BA; DeBenedette MA; Watts TH; Berinstein NL
    J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
    Seeley BM; Barthel SW; To WC; Kjaergaard J; Shu S; Plautz GE
    Otolaryngol Head Neck Surg; 2001 Apr; 124(4):436-41. PubMed ID: 11283503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Engraftment and activity of anti-CD3-activated human peripheral blood lymphocytes transferred into mice with severe combined immune deficiency.
    Murphy WJ; Conlon KC; Sayers TJ; Wiltrout RH; Back TC; Ortaldo JR; Longo DL
    J Immunol; 1993 Apr; 150(8 Pt 1):3634-42. PubMed ID: 8468492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy via gene therapy: comparison of the effects of tumor cells transduced with the interleukin-2, interleukin-6, or interferon-gamma genes.
    Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
    J Immunother Emphasis Tumor Immunol; 1993 Oct; 14(3):191-201. PubMed ID: 7905286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M; Plautz GE; Shu S
    Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.
    Kunkel P; Ulbricht U; Bohlen P; Brockmann MA; Fillbrandt R; Stavrou D; Westphal M; Lamszus K
    Cancer Res; 2001 Sep; 61(18):6624-8. PubMed ID: 11559524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.
    Roychowdhury S; May KF; Tzou KS; Lin T; Bhatt D; Freud AG; Guimond M; Ferketich AK; Liu Y; Caligiuri MA
    Cancer Res; 2004 Nov; 64(21):8062-7. PubMed ID: 15520217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.